ANI Pharmaceuticals to Acquire Two NDAs from Merck for $75 Million – Transaction Highlights:– Corticotropin-zinc hydroxide, 40 units/mL, NDA #009854– Assets will be acquired by foreign subsidiary to achieve more favorable tax treatment for ANI– Acquisition significantly advances ANI’s core strategy of re-commercializing previously approved products– Conference call to discuss transaction scheduled today at 10:00am […]

The chief executive officer, Edward Kaye, of Cambridge, Mass.-based Sarepta Therapeutics (SRPT) recently indicated the company is looking to acquire a drug to treat Duchenne muscular dystrophy (DMD).   On June 29, 2015, Sarepta announced it had completed the rolling submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) […]